

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
9 June 2005 (09.06.2005)

PCT

(10) International Publication Number  
**WO 2005/051895 A1**

(51) International Patent Classification<sup>7</sup>: **C07C 237/20**,  
C07D 295/02, C07C 237/24, 271/24, 323/29, 255/50,  
C07D 319/18, 313/08, 307/79, 207/09, 333/08, A61P  
9/12, A61K 31/165, 31/325, 31/44

(21) International Application Number:  
PCT/EP2004/013412

(22) International Filing Date:  
25 November 2004 (25.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/525,374 26 November 2003 (26.11.2003) US

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH**  
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(71) Applicant and

(72) Inventor (for all designated States except AT, US): **NO-  
VARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel  
(CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAESCHLIN**,  
Daniel, Kaspar [CH/CH]; In der Schappe 141, CH-4144  
Arlesheim (CH). **MAIBAUM**, Jürgen, Klaus [DE/DE];  
Lütemannsweg 14/1, 79576 Weil-Haltingen (DE). **SELL-  
NER**, Holger [DE/CH]; Keltenstr. 37, CH-4106 Therwil  
(CH).

(74) Agent: **GRUBB, Phillip**; Novartis AG, Corporate Intellec-  
tual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: ORGANIC COMPOUNDS



(I)

(57) Abstract: Disclosed are  $\delta$ -amino- $\gamma$ -hy-  
droxy- $\omega$ -aryl-alkanoic acid amide compounds of  
formula (I) and the salts thereof, having renin-inhibiting  
properties. Also disclosed are pharmaceutical  
compositions comprising these compounds and methods  
of administering them for the treatment of hypertension,  
atherosclerosis, unstable coronary syndrome, congestive  
heart failure, cardiac hypertrophy, cardiac fibrosis,  
cardiomyopathy postinfarction, unstable coronary  
syndrome, diastolic dysfunction, chronic kidney disease,  
hepatic fibrosis, complications resulting from diabetes,

such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.